Role of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: Predicting malignant potential pre-operatively

Journal of Gastric Cancer

Volumn 11, Issue 3, 2011, Pages 173-179

  Park, Jeon Woo ^a   Cho, Chang Ho ^a   Jeong, Duck Su ^a   Chae, Hyun Dong ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

FDG PET CT; GIST; Ki 67 index; Maximum SUV uptake; NIH classification

Indexed keywords

EID: 84863764312     PISSN: 2093582X     EISSN: 20935641     Source Type: Journal    
DOI: 10.5230/jgc.2011.11.3.173     Document Type: Article

References (30)

1. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(Suppl 5):S39-51.
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-1269.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and diflerential diagnosis. Virchows Arch 2001;438:1-12.
4. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-1095.
5. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al. Eflect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-4300.
6. Franquemont DW. Diflerentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-47.
7. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999;34:416-424.
8. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-676.
9. Amin MB, Ma CK, Linden MD, Kubus JJ, Zarbo RJ. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Correlation with mitotic count and clinical outcome. Am J Clin Pathol 1993;100:428-432.
10. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465.
11. Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006;42:1720-1727.
12. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005;29:1429-1435.
13. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-483.
14. Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any diflerence? Monogr Pathol 1990;(31):220-246.
15. Somerhausen Nde S, Fletcher CD. Gastrointestinal stromal tumours: an update. Sarcoma 1998;2:133-141.
16. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer 1977;39:255-262.
17. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985;56:2242-2250.
18. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
19. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
20. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-65.
21. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990;96(Pt 1):121-129.
22. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
23. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11.
24. Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol 2000;99:563-570.
25. Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000;27:179-189.
26. Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000;19:471-475.
27. Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007;42:633-641.
28. Franquemont DW. Diflerentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-47.
29. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
30. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005;11(2 Pt 1):638-645.